NoTiCe,..
my purpose to post this information is solely for adding to the due diligence of this company, HEB. and to bring to any and all HEB investors complete infomration that is out for all to discern.
the moderators at the HEB iHub forum choose to delete this information. by deleting this information they are taking the position that they will not allow the forum to read this information which might assist investors a better understanding of what 'might' be in the cards for HEB. not that it will occur but with information of a pattern in this market sector DNDN is in it might spillover to HEB.
why would the moderators remove possible crucial information that investors in HEB would want to know ? i don't have that answer,...but it's not a fair playing field that is being created at the HEB iHub forum if they are choosing to delete information that is in fact on topic and in fact educates the HEB investor what to look out for. at least allow the forum participants to read this and bring discussion. they have the right to have all information that could have potential influence on the share price. you, as moderator(s), do not have the right to remove what will soon be on the next page and expose investors to potential loss.
as much as everyone would like to believe this type of action couldn't happen to HEB,..it in fact can occur with HEB.
here is what was deleted,...
yes,..it could be the next DNDN (share price moves high parabolically),...and not STRICTLY in the positive sense (shorts drive share price down parabolically),...which is why you, if you are a shareholder in HEB, need to read this;
Michael Milken, 60,000 Deaths, and the Story of Dendreon (Chapter 1 of 15)
http://www.deepcapture.com/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/
What follows is part 1 of a 15-part series. The remaining installments will appear on Deep Capture over the next several weeks, after which point the story will be published in its entirety. It is a story about the travails of just one small company, but it describes market machinations that have affected hundreds of other companies, and it contains a larger message for anyone concerned about the “deep capture” of our nation’s media and regulatory bodies.
* * * * * * * *
This story, like too many others, begins with Jim Cramer, the CNBC personality, making “a mistake.”
On September 26, 2005, Cramer announced to his television audience the sad news (punctuated by funny sound effects – a clown horn, a crashing airplane) that Provenge, an experimental treatment for prostate cancer, had flopped. Thousands of end-stage patients had been pinning their hopes on Provenge, but according to Cramer the treatment had just been rejected by the Food & Drug Administration. It would never go to market.
This seemed odd, because Dendreon (NASDAQ: DNDN), the company developing Provenge, had not yet submitted an application for FDA approval. As everybody in the biotech investment community knew, Dendreon had, in fact, only recently completed Phase 3 clinical trials and probably would not face scrutiny from an FDA advisory panel for at least another year.
As for the likelihood that the advisory panel would eventually vote in favor of Provenge, the odds looked quite good. The Phase 3 trials had demonstrated that Provenge significantly increased patient survival with only minimal side-effects, such as a few days of mild fever. Moreover, Provenge was an altogether different sort of treatment – one that fought tumors by boosting patients’ immune systems rather than subjecting them to the ravages of chemotherapy.
Provenge was not a magical elixir of life, but Dendreon was doing more than just developing a new technology. It was pioneering a treatment that could revolutionize the way that doctors fight prostate cancer. By some conservative estimates, the market for Provenge alone could reach more than $2 billion a year. If the treatment could be applied to other cancers, the market would be even larger.
The morning after Cramer declared Dendreon and Provenge to be dead in the water, Mark Haines, the anchor of CNBC’s “Squawk Box” program, apologized for Cramer’s “mistake.” That afternoon, at an important UBS investor conference, Dendreon presented still more promising data. This would normally have given a significant boost to the company’s stock price, but the value of Dendreon’s shares stayed flat for the day, and then began a gradual decline.
This had partly to do with Cramer. The next evening, on his “Mad Money” program, the journalist (or entertainer, or self-confessed criminal, or… whatever Cramer is) acknowledged that the FDA had not yet rejected Provenge, but drawing upon his medical expertise, Cramer maintained that Provenge was not effective. In characteristically level-headed fashion, he announced that Dendreon shareholders were drunken, carousing, gambling Falstaffs who “might as well take their money to Vegas.”
Dendreon, Cramer added (rather ominously), was a “battleground stock.”
story continues. chapter 2,3 & 4 are posted also. http://www.deepcapture.com/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/
News 
Market Data 
Discover 
